Core Laboratories upgraded to Neutral from Sell at Citi
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2025
0mins
Should l Buy CLB?
Analyst Upgrade: Citi analyst Scott Gruber upgraded Core Laboratories from Sell to Neutral with a new price target of $16, indicating a more balanced risk/reward scenario after a 15% decline in stock value this year.
Geopolitical Impact: The potential easing of Russia/Ukraine tensions could positively affect crude oil assay demand, serving as a catalyst for Core Laboratories' performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLB
Wall Street analysts forecast CLB stock price to fall
1 Analyst Rating
0 Buy
0 Hold
1 Sell
Moderate Sell
Current: 18.150
Low
11.50
Averages
11.50
High
11.50
Current: 18.150
Low
11.50
Averages
11.50
High
11.50
About CLB
Core Laboratories Inc. is a provider of proprietary and patented reservoir description and production enhancement services and products for the oil and gas industry. The Company helps to evaluate and improve reservoir performance and increase oil and gas recovery from new and existing fields. It makes measurements of reservoir rocks, reservoir fluids (crude oil, natural gas and water) and their derived products. It assists clients in evaluating subsurface targets associated with carbon capture and sequestration projects or initiatives. Its segments include Reservoir Description, which provides laboratory-based analytical and field services to characterize the properties of crude oil and crude oil-derived products for the oil and gas industry, and Production Enhancement segment, which provides integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Core Laboratories Declares Quarterly Dividend of $0.01
- Quarterly Dividend Declaration: Core Laboratories has declared a quarterly dividend of $0.01 per share, maintaining consistency with previous dividends, which reflects the company's stability in the current economic environment.
- Dividend Yield: The forward yield of this dividend stands at 0.2%, indicating the company's ongoing commitment to shareholder returns while also suggesting a healthy cash flow situation.
- Payment Schedule: The dividend will be payable on March 9, with a record date of February 16 and an ex-dividend date of February 13, providing investors with a clear timeline that aids in their investment decisions.
- Historical Performance Context: Core Laboratories' dividend policy aligns with its historical earnings data, demonstrating the company's continued efforts in providing technology to replace tier-1 oil inventory, thereby enhancing its competitive position in the industry.
See More
Core Laboratories Q4 Earnings Exceed Expectations
- Earnings Beat: Core Laboratories reported a Q4 non-GAAP EPS of $0.21, surpassing expectations by $0.02, indicating robust profitability and boosting investor confidence in the company's financial health.
- Significant Revenue Growth: The company achieved Q4 revenue of $138.3 million, a 7.0% year-over-year increase, exceeding analyst expectations by $7.9 million, showcasing Core Laboratories' strong performance amid recovering market demand and solidifying its market position.
- Technology Replacement Potential: Core Laboratories is focused on providing technology to replace tier-1 oil inventory, and as the global energy transition accelerates, the adoption of this technology is expected to create new growth opportunities and enhance its competitive edge in the industry.
- Positive Future Outlook: The earnings beat not only reflects current market performance but also lays a foundation for sustained growth, attracting increased investor interest as demand for efficient energy solutions rises.
See More
Core Laboratories to Announce Q4 Earnings on February 4
- Earnings Announcement Schedule: Core Laboratories is set to release its Q4 2023 earnings report on February 4 after market close, with consensus EPS estimates at $0.19, reflecting a 13.6% year-over-year decline, while revenue is expected to reach $130.4 million, a 0.9% year-over-year increase.
- Historical Performance Review: Over the past two years, Core Laboratories has exceeded EPS estimates 63% of the time and revenue estimates 50% of the time, indicating a degree of stability in its earnings performance amidst market fluctuations.
- Expectation Revision Dynamics: In the last three months, EPS estimates have seen one upward revision with no downward adjustments, while revenue estimates have experienced one upward and one downward revision, suggesting mixed market sentiment regarding the company's future performance.
- Market Focus: Core Laboratories provides technology aimed at replacing Tier-1 oil inventory, and the market's attention on its earnings report extends beyond the numbers to how the company navigates industry challenges and its potential for future growth.
See More
Christina Lake Cannabis Sells 99 Acres of Non-Core Land for $551,000
- Asset Disposition: Christina Lake Cannabis has completed the sale of 99 acres of non-core land in British Columbia for gross proceeds of $551,000, which will enhance the company's liquidity and improve its balance sheet.
- Strategic Focus: The land sale follows a reassessment of assets post-Midway acquisition, ensuring the company remains focused on its core operating assets to support long-term growth objectives.
- Use of Proceeds: Proceeds from the sale will be allocated to general working capital, further enhancing financial flexibility and supporting future business expansion.
- Market Positioning: As a licensed cannabis producer with over 950,000 square feet of outdoor grow space, Christina Lake Cannabis aims to maintain its competitive edge through this asset optimization in a highly competitive market.
See More
Core Laboratories Schedules Q4 2025 Earnings Call for February 5, 2026
- Earnings Call Schedule: Core Laboratories will host its Q4 2025 earnings call on February 5, 2026, at 7:30 a.m. CST, where executives will discuss financial and operational results, ensuring timely access to critical information for investors.
- Earnings Release Preview: The company will issue its earnings press release after market close on February 4, 2026, which can be accessed through the company’s website, enhancing transparency and boosting market confidence.
- Webcast Registration: Investors are required to log on to the website at least 15 minutes prior to the call to register for the listen-only webcast, ensuring efficient information dissemination.
- Replay and Transcript Availability: For those unable to attend the live session, a replay and transcript will be available shortly after the call on the company’s website, further improving accessibility of information and communication with investors.
See More
Core Labs Posts Flat Revenue in Q2
Q2 2025 Financial Performance: Core Laboratories reported Q2 2025 revenue of $130.2 million, slightly exceeding expectations but flat year-over-year, with adjusted EPS at $0.19, reflecting a 13.6% decline from the previous year. The company emphasized operational progress in international markets and maintained a focus on technological innovation and cost management.
Future Outlook and Risks: For Q3 2025, Core Laboratories forecasts revenue between $127.5 million and $134.5 million, with potential risks stemming from oil and gas industry cycles, U.S. market unpredictability, and tariffs affecting production materials. The company plans to maintain its dividend at $0.01 per share while prioritizing free cash generation and reinvestment in technology.
See More
Core Laboratories Declares Quarterly Dividend of $0.01
- Quarterly Dividend Declaration: Core Laboratories has declared a quarterly dividend of $0.01 per share, maintaining consistency with previous dividends, which reflects the company's stability in the current economic environment.
- Dividend Yield: The forward yield of this dividend stands at 0.2%, indicating the company's ongoing commitment to shareholder returns while also suggesting a healthy cash flow situation.
- Payment Schedule: The dividend will be payable on March 9, with a record date of February 16 and an ex-dividend date of February 13, providing investors with a clear timeline that aids in their investment decisions.
- Historical Performance Context: Core Laboratories' dividend policy aligns with its historical earnings data, demonstrating the company's continued efforts in providing technology to replace tier-1 oil inventory, thereby enhancing its competitive position in the industry.
See More
Core Laboratories Q4 Earnings Exceed Expectations
- Earnings Beat: Core Laboratories reported a Q4 non-GAAP EPS of $0.21, surpassing expectations by $0.02, indicating robust profitability and boosting investor confidence in the company's financial health.
- Significant Revenue Growth: The company achieved Q4 revenue of $138.3 million, a 7.0% year-over-year increase, exceeding analyst expectations by $7.9 million, showcasing Core Laboratories' strong performance amid recovering market demand and solidifying its market position.
- Technology Replacement Potential: Core Laboratories is focused on providing technology to replace tier-1 oil inventory, and as the global energy transition accelerates, the adoption of this technology is expected to create new growth opportunities and enhance its competitive edge in the industry.
- Positive Future Outlook: The earnings beat not only reflects current market performance but also lays a foundation for sustained growth, attracting increased investor interest as demand for efficient energy solutions rises.
See More
Core Laboratories to Announce Q4 Earnings on February 4
- Earnings Announcement Schedule: Core Laboratories is set to release its Q4 2023 earnings report on February 4 after market close, with consensus EPS estimates at $0.19, reflecting a 13.6% year-over-year decline, while revenue is expected to reach $130.4 million, a 0.9% year-over-year increase.
- Historical Performance Review: Over the past two years, Core Laboratories has exceeded EPS estimates 63% of the time and revenue estimates 50% of the time, indicating a degree of stability in its earnings performance amidst market fluctuations.
- Expectation Revision Dynamics: In the last three months, EPS estimates have seen one upward revision with no downward adjustments, while revenue estimates have experienced one upward and one downward revision, suggesting mixed market sentiment regarding the company's future performance.
- Market Focus: Core Laboratories provides technology aimed at replacing Tier-1 oil inventory, and the market's attention on its earnings report extends beyond the numbers to how the company navigates industry challenges and its potential for future growth.
See More
Christina Lake Cannabis Sells 99 Acres of Non-Core Land for $551,000
- Asset Disposition: Christina Lake Cannabis has completed the sale of 99 acres of non-core land in British Columbia for gross proceeds of $551,000, which will enhance the company's liquidity and improve its balance sheet.
- Strategic Focus: The land sale follows a reassessment of assets post-Midway acquisition, ensuring the company remains focused on its core operating assets to support long-term growth objectives.
- Use of Proceeds: Proceeds from the sale will be allocated to general working capital, further enhancing financial flexibility and supporting future business expansion.
- Market Positioning: As a licensed cannabis producer with over 950,000 square feet of outdoor grow space, Christina Lake Cannabis aims to maintain its competitive edge through this asset optimization in a highly competitive market.
See More
Core Laboratories Schedules Q4 2025 Earnings Call for February 5, 2026
- Earnings Call Schedule: Core Laboratories will host its Q4 2025 earnings call on February 5, 2026, at 7:30 a.m. CST, where executives will discuss financial and operational results, ensuring timely access to critical information for investors.
- Earnings Release Preview: The company will issue its earnings press release after market close on February 4, 2026, which can be accessed through the company’s website, enhancing transparency and boosting market confidence.
- Webcast Registration: Investors are required to log on to the website at least 15 minutes prior to the call to register for the listen-only webcast, ensuring efficient information dissemination.
- Replay and Transcript Availability: For those unable to attend the live session, a replay and transcript will be available shortly after the call on the company’s website, further improving accessibility of information and communication with investors.
See More
Core Labs Posts Flat Revenue in Q2
Q2 2025 Financial Performance: Core Laboratories reported Q2 2025 revenue of $130.2 million, slightly exceeding expectations but flat year-over-year, with adjusted EPS at $0.19, reflecting a 13.6% decline from the previous year. The company emphasized operational progress in international markets and maintained a focus on technological innovation and cost management.
Future Outlook and Risks: For Q3 2025, Core Laboratories forecasts revenue between $127.5 million and $134.5 million, with potential risks stemming from oil and gas industry cycles, U.S. market unpredictability, and tariffs affecting production materials. The company plans to maintain its dividend at $0.01 per share while prioritizing free cash generation and reinvestment in technology.
See More
